Overview
Axsome Therapeutics is a commercial-stage biopharmaceutical company developing novel therapies for CNS disorders, with FDA-approved products including Auvelity for major depressive disorder and Sunosi for excessive daytime sleepiness. Their pipeline spans depression, Alzheimer's agitation, migraine, and narcolepsy.
More in Neuropharmaceuticals
Latest industry news
FDA Grants De Novo Approval to Modius Spero, Clearing First Neuromodulation Device for PTSD
2026-09-03 · Policy
Butterfly Network's BCI Chip Licensing Deal Rattles Investors as Shares Drop Nearly 10%
2026-09-02 · Industry
Merge Labs and Butterfly Network Unite to Push Ultrasound-Based BCIs Into the Mainstream
2026-09-01 · Industry
FDA Grants CorTec Second Breakthrough Device Designation for Its Brain-Computer Interface
2026-08-31 · Policy
Company details
Category
💊 Neuropharmaceuticals
Location
New York, USA
Funding
Public · NASDAQ: AXSM
Website
www.axsome.comListed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →